Ramon Arens and his group have discovered biomarkers that may predict whether a patient responds to immunotherapy. In this way, the treatment plan can be evaluated in time and per patient with cancer and possibly adjusted.
The group of Yanling Xiao and Jannie Borst has a recent publication in Nature Communications that shows how CD4+ T cells promote tumor immunity.
Despite their low abundance, presence of classical type 1 dendritic cells (cDC1) in tumors positively correlates with patient survival. The research demonstrates that cDC1 are key for relaying CD4+ T-cell help for cytotoxic T cell (CTL) responses.
Looking for information on one of our topics, a new place to conduct your research or connect to experienced researchers to join forces with? Feel free to contact us!